Drug intelligence / Profile preview

Cairo Univ. EGFR/VEGFR2 compound 3e

Development stage
Preclinical
Lead developer
Cairo University
01

Overview

Cairo Univ. EGFR/VEGFR2 compound 3e: sourced facts only. name: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; target: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; target: "Compound 3e was the most potent against EGFR and VEGFR2 with IC50 values of 0.142 and 0.071 μM compared to erlotinib and axitinib with IC50 values of 0.064 and 0.050 μM, respectively."; developer: "Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Cairo University, 11562 Cairo, Egypt."; stage: "Boyden chamber and wound healing assays demonstrated that compound 3e could impair cell migration and invasion in T47D cells."

02

Targets

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Cairo Univ. EGFR/VEGFR2 compound 3e.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cairo Univ. EGFR/VEGFR2 compound 3e.

Work on Cairo Univ. EGFR/VEGFR2 compound 3e? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call